Cormedix INC Form 4 insider transactions

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, acquired 36,006 shares of common stock through the vesting of performance stock units.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, achieved performance conditions for 36,006 stock units, subject to future time-based vesting.

CorMedix Inc. CEO Joseph Todisco has achieved performance conditions for 77,156 performance stock units, subject to future time-based vesting.

CorMedix Inc.'s EVP and CFO, Susan Blum, reported the acquisition of restricted stock units and the disposition of shares for tax withholding purposes.

CorMedix Chief Legal Officer Beth Zelnick Kaufman reported the grant of 72,820 restricted stock units and the disposition of 8,803 shares for tax withholding.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, was granted 93,010 restricted stock units, with a portion immediately vesting and the remainder vesting over three years.

CorMedix Inc. CEO Joseph Todisco reported the acquisition of 225,900 restricted stock units and the disposition of 27,306 shares for tax purposes.

CorMedix Inc. Director Myron Kaplan was granted 30,453 restricted stock units, vesting in full on January 26, 2027.

CorMedix Inc. Director Janet Dillione was granted 30,453 restricted stock units, vesting in January 2027.

CorMedix Inc. Director Steven W. Lefkowitz was granted 30,453 restricted stock units, which will vest in full on January 26, 2027.

CorMedix Inc. Director Alan W. Dunton reported the acquisition of 30,453 restricted stock units, vesting in January 2027.

CorMedix Inc. Director Gregory Duncan received 30,453 restricted stock units, increasing his beneficial ownership to 68,786 shares.

CorMedix Inc. Director Robert Stewart was granted 30,453 restricted stock units, vesting in full on January 26, 2027.

CorMedix Inc. Director Janet Dillione sold 10,000 shares of common stock at a weighted average price of $6.88 per share.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported the disposition of 5,794 shares of common stock at $7.15 per share, attributing the late filing to an administrative error.

CorMedix CEO Joseph Todisco reported recent transactions involving common stock and stock options, including option exercises and tax-related dispositions.

CorMedix Inc.'s Chief Commercial Officer, Michael David Seckler, was granted 133,156 Restricted Stock Units vesting over four years.

CorMedix Inc. Director Steven W. Lefkowitz acquired 15,000 shares of common stock through the exercise of vested stock options at $5.63 per share.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported the disposition of 10,895 shares of common stock at $12.16 per share.

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, reported the sale of 11,333 shares of common stock at $12.16 per share to cover tax obligations.

CorMedix Inc. Director Alan W. Dunton exercised options and subsequently sold 20,000 shares of common stock for $13 per share under a Rule 10b5-1 plan.

CorMedix Inc. CEO Joseph Todisco exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

CorMedix Director Janet Dillione exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged trading plan.

CorMedix Inc. Director Steven W. Lefkowitz reported the sale of 40,000 shares of common stock at a weighted average price of $11.88 per share.

CorMedix Director Janet Dillione exercised stock options and subsequently sold an equal number of shares under a Rule 10b5-1 plan.

CorMedix Inc. Director Janet Dillione exercised stock options and subsequently sold an equivalent number of common shares.

CorMedix Inc. Director Janet Dillione sold 30,000 shares of common stock at a weighted average price of $11.42 on November 14, 2025, pursuant to a Rule 10b5-1 plan.

CorMedix Inc. Director Myron Kaplan purchased 25,000 shares of common stock at a weighted average price of $11.02 on October 23, 2025.

CorMedix Inc. Director Gregory Scott Duncan exercised 13,333 stock options, acquiring common stock at $8.32 per share.

CorMedix Inc. Director Alan W. Dunton exercised stock options and subsequently sold 10,000 shares of common stock for personal liquidity.